Tempest Therapeutics, spun out of Versant Ventures drug-discovery labs, is developing unique portfolio of small molecule therapeutics for novel and key emerging targets in immuno-oncology.
Tempest Therapeutics Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://www.tempesttx.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
AddressOne Sansome Street Suite 3690, CA 94104San FranciscoUnited States
One Sansome Street Suite 3690, CA 94104
San Francisco
United States
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/tempesttx” connections=”true” suffix=””]
In Mar 2018, Tempest Therapeutics raised $70 Mn in Series B financing led by founding investor Versant Ventures and by F-Prime Capital, Quan Capital, Lilly Asia Ventures, Foresite Capital and Eight Roads Ventures.